Trials / Completed
CompletedNCT01910194
Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled on Diet and Oral Antidiabetic Medication
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
Detailed description
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Luyxumia versus Lantus |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2013-07-29
- Last updated
- 2015-01-22
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01910194. Inclusion in this directory is not an endorsement.